Last 12 months
Inside the activity.
0 purchase rows · 49 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 13 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 11 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 11 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 14 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC |
Gutierrez-Ramos Jose-CarlosDirector
|
GrantOrdinary Shares | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000917 · form4-01062025_070104.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 19:30 UTC |
Kender Richard NDirector
|
GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000918 · form4-01062025_070106.xml · derivative · entry 2 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Ordinary Shares · 12,500 shares Expires 2035-01-02 F3 · derivative.exercise_date: This option shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 19:30 UTC |
Kender Richard NDirector
|
GrantOrdinary Shares | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000918 · form4-01062025_070106.xml · nonDerivative · entry 1 Kender Richard N · CIK 0001381205 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 19:30 UTC |
Legault PierreDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000929 · form4-01062025_070130.xml · derivative · entry 2 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Ordinary Shares · 25,000 shares Expires 2035-01-02 F3 · derivative.exercise_date: This option shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 19:30 UTC |
Legault PierreDirector
|
GrantOrdinary Shares | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000929 · form4-01062025_070130.xml · nonDerivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,000 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 19:30 UTC |
Arroyo SantiagoCHIEF DEVELOPMENT OFFICER
|
GrantEmployee Stock Option (right to buy) · Derivative | 87,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000926 · form4-01062025_070123.xml · derivative · entry 3 Arroyo Santiago · CIK 0001706857 · CHIEF DEVELOPMENT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,000 Underlying: Ordinary Shares · 87,000 shares Expires 2035-01-02 F5 · derivative.exercise_date: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2026 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 19:30 UTC |
Arroyo SantiagoCHIEF DEVELOPMENT OFFICER
|
SaleOrdinary Shares | 4,943 | $14.09 | $69,646.87 |
DisclosureSEC source: 0001415889-25-000926 · form4-01062025_070123.xml · nonDerivative · entry 2 Arroyo Santiago · CIK 0001706857 · CHIEF DEVELOPMENT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,057 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.90 to $14.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 19:30 UTC |
Arroyo SantiagoCHIEF DEVELOPMENT OFFICER
|
GrantOrdinary Shares | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000926 · form4-01062025_070123.xml · nonDerivative · entry 1 Arroyo Santiago · CIK 0001706857 · CHIEF DEVELOPMENT OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,000 F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2026 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC |
Thompson Travis AlvinCHIEF ACCOUNTING OFFICER
|
GrantEmployee Stock Option (right to buy) · Derivative | 43,500 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000928 · form4-01062025_070128.xml · derivative · entry 5 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,500 Underlying: Ordinary Shares · 43,500 shares Expires 2035-01-02 F7 · derivative.exercise_date: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2026 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC |
Thompson Travis AlvinCHIEF ACCOUNTING OFFICER
|
SaleOrdinary Shares | 1,750 | $14.09 | $24,657.50 |
DisclosureSEC source: 0001415889-25-000928 · form4-01062025_070128.xml · nonDerivative · entry 2 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,991 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.90 to $14.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) and (5). Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC |
Thompson Travis AlvinCHIEF ACCOUNTING OFFICER
|
GrantOrdinary Shares | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000928 · form4-01062025_070128.xml · nonDerivative · entry 1 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,741 F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2026 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC |
Young AlethiaChief Financial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 87,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000927 · form4-01062025_070126.xml · derivative · entry 3 Young Alethia · CIK 0001918147 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,000 Underlying: Ordinary Shares · 87,000 shares Expires 2035-01-02 F5 · derivative.exercise_date: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2026 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC |
Young AlethiaChief Financial Officer
|
SaleOrdinary Shares | 1,395 | $14.09 | $19,655.55 |
DisclosureSEC source: 0001415889-25-000927 · form4-01062025_070126.xml · nonDerivative · entry 2 Young Alethia · CIK 0001918147 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,605 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.90 to $14.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC |
Young AlethiaChief Financial Officer
|
GrantOrdinary Shares | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000927 · form4-01062025_070126.xml · nonDerivative · entry 1 Young Alethia · CIK 0001918147 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,000 F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2026 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC |
Crockett NigelCHIEF BUSINESS OFFICER
|
GrantEmployee Stock Option (right to buy) · Derivative | 21,750 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000925 · form4-01062025_070121.xml · derivative · entry 4 Crockett Nigel · CIK 0001788580 · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,750 Underlying: Ordinary Shares · 21,750 shares Expires 2035-01-02 F6 · derivative.exercise_date: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2026 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC |
Crockett NigelCHIEF BUSINESS OFFICER
|
SaleOrdinary Shares | 2,583 | $14.09 | $36,394.47 |
DisclosureSEC source: 0001415889-25-000925 · form4-01062025_070121.xml · nonDerivative · entry 2 Crockett Nigel · CIK 0001788580 · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,989 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.90 to $14.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) and (5). Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC |
Crockett NigelCHIEF BUSINESS OFFICER
|
GrantOrdinary Shares | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000925 · form4-01062025_070121.xml · nonDerivative · entry 1 Crockett Nigel · CIK 0001788580 · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,572 F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2026 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC |
Milnes AlistairCHIEF OPERATING OFFICER
|
GrantEmployee Stock Option (right to buy) · Derivative | 87,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000924 · form4-01062025_070119.xml · derivative · entry 4 Milnes Alistair · CIK 0001901321 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,000 Underlying: Ordinary Shares · 87,000 shares Expires 2035-01-02 F6 · derivative.exercise_date: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2026 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC |
Milnes AlistairCHIEF OPERATING OFFICER
|
SaleOrdinary Shares | 4,578 | $14.09 | $64,504.02 |
DisclosureSEC source: 0001415889-25-000924 · form4-01062025_070119.xml · nonDerivative · entry 2 Milnes Alistair · CIK 0001901321 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,724 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.90 to $14.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) and (5). Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC |
Milnes AlistairCHIEF OPERATING OFFICER
|
GrantOrdinary Shares | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000924 · form4-01062025_070119.xml · nonDerivative · entry 1 Milnes Alistair · CIK 0001901321 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,302 F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2026 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC |
Skynner MichaelCHIEF TECHNOLOGY OFFICER
|
GrantEmployee Stock Option (right to buy) · Derivative | 87,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000923 · form4-01062025_070117.xml · derivative · entry 4 Skynner Michael · CIK 0001776582 · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,000 Underlying: Ordinary Shares · 87,000 shares Expires 2035-01-02 F6 · derivative.exercise_date: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2026 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC |
Skynner MichaelCHIEF TECHNOLOGY OFFICER
|
SaleOrdinary Shares | 3,287 | $14.09 | $46,313.83 |
DisclosureSEC source: 0001415889-25-000923 · form4-01062025_070117.xml · nonDerivative · entry 2 Skynner Michael · CIK 0001776582 · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,658 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.90 to $14.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) and (5). Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC |
Skynner MichaelCHIEF TECHNOLOGY OFFICER
|
GrantOrdinary Shares | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000923 · form4-01062025_070117.xml · nonDerivative · entry 1 Skynner Michael · CIK 0001776582 · CHIEF TECHNOLOGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,945 F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2026 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC |
Winter Gregory PaulDirector
|
GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000920 · form4-01062025_070110.xml · derivative · entry 2 Winter Gregory Paul · CIK 0001777021 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Ordinary Shares · 12,500 shares Expires 2035-01-02 F3 · derivative.exercise_date: This option shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC |
Winter Gregory PaulDirector
|
GrantOrdinary Shares | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000920 · form4-01062025_070110.xml · nonDerivative · entry 1 Winter Gregory Paul · CIK 0001777021 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,927 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC |
Sands Stephen H.Director
|
GrantStock Option (right to buy) · Derivative | 10,787 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000919 · form4-01062025_070108.xml · derivative · entry 2 Sands Stephen H. · CIK 0001913319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,787 Underlying: Ordinary Shares · 10,787 shares Expires 2035-01-02 F3 · derivative.exercise_date: This option shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC |
Sands Stephen H.Director
|
GrantOrdinary Shares | 5,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000919 · form4-01062025_070108.xml · nonDerivative · entry 1 Sands Stephen H. · CIK 0001913319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,393 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 23:03 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
PurchaseAmerican Depositary Shares | 457,631 | $15.34 | $7,020,883.28 |
DisclosureSEC source: 0000950170-24-137446 · ownership.xml · nonDerivative · entry 10 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 9,995,274 F12 · price: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $15.11 to $15.49, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote. F3 · ownership.nature: Baker Bros. Advisors LP ("the Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by or held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F5 · ownership.nature: Includes beneficial ownership of 12,000 ADS issuable upon the vesting of restricted stock units (each an "RSU") payable solely in ADS previously issued to Felix J. Baker, in his capacity as a director of the Issuer pursuant to the Issuer's 2020 Equity Incentive Plan (the "2020 Plan") of which the Funds may be deemed to own a portion. The RSUs vest in three equal annual installments beginning on April 18, 2025, subject to Felix J. Baker's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Felix J. Baker serves on the Board as a representative of the Funds and their affiliates and control persons. Each RSU represents a contingent right to receive one Ordinary Share of the Issuer. F6 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the ADS received upon vesting of RSUs and non-qualified share options convertible solely into ADS of the Issuer ("Share Options") received as a result of his service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the ADS upon vesting of RSUs, Share Options, and ADS received upon the exercise of Share Options (i.e. no direct pecuniary interest) issued as compensation for such Board service. F7 · ownership.nature: The Adviser has voting and dispositive power over the Share Options, RSUs and any ADS received as a result of the exercise of Share Options or vesting of RSUs. F8 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 23:03 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
PurchaseAmerican Depositary Shares | 42,369 | $15.34 | $650,016.72 |
DisclosureSEC source: 0000950170-24-137446 · ownership.xml · nonDerivative · entry 9 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 914,083 F12 · price: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $15.11 to $15.49, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote. F2 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. F3 · ownership.nature: Baker Bros. Advisors LP ("the Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by or held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F5 · ownership.nature: Includes beneficial ownership of 12,000 ADS issuable upon the vesting of restricted stock units (each an "RSU") payable solely in ADS previously issued to Felix J. Baker, in his capacity as a director of the Issuer pursuant to the Issuer's 2020 Equity Incentive Plan (the "2020 Plan") of which the Funds may be deemed to own a portion. The RSUs vest in three equal annual installments beginning on April 18, 2025, subject to Felix J. Baker's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Felix J. Baker serves on the Board as a representative of the Funds and their affiliates and control persons. Each RSU represents a contingent right to receive one Ordinary Share of the Issuer. F6 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the ADS received upon vesting of RSUs and non-qualified share options convertible solely into ADS of the Issuer ("Share Options") received as a result of his service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the ADS upon vesting of RSUs, Share Options, and ADS received upon the exercise of Share Options (i.e. no direct pecuniary interest) issued as compensation for such Board service. F7 · ownership.nature: The Adviser has voting and dispositive power over the Share Options, RSUs and any ADS received as a result of the exercise of Share Options or vesting of RSUs. Read SEC document |
| December 13, 2024 Filed Dec 17, 2024 23:03 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
PurchaseAmerican Depositary Shares | 566,814 | $13.80 | $7,824,300.46 |
DisclosureSEC source: 0000950170-24-137446 · ownership.xml · nonDerivative · entry 8 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 9,537,643 F11 · price: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $13.48 to $14.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote. F3 · ownership.nature: Baker Bros. Advisors LP ("the Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by or held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F5 · ownership.nature: Includes beneficial ownership of 12,000 ADS issuable upon the vesting of restricted stock units (each an "RSU") payable solely in ADS previously issued to Felix J. Baker, in his capacity as a director of the Issuer pursuant to the Issuer's 2020 Equity Incentive Plan (the "2020 Plan") of which the Funds may be deemed to own a portion. The RSUs vest in three equal annual installments beginning on April 18, 2025, subject to Felix J. Baker's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Felix J. Baker serves on the Board as a representative of the Funds and their affiliates and control persons. Each RSU represents a contingent right to receive one Ordinary Share of the Issuer. F6 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the ADS received upon vesting of RSUs and non-qualified share options convertible solely into ADS of the Issuer ("Share Options") received as a result of his service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the ADS upon vesting of RSUs, Share Options, and ADS received upon the exercise of Share Options (i.e. no direct pecuniary interest) issued as compensation for such Board service. F7 · ownership.nature: The Adviser has voting and dispositive power over the Share Options, RSUs and any ADS received as a result of the exercise of Share Options or vesting of RSUs. F8 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. Read SEC document |
| December 13, 2024 Filed Dec 17, 2024 23:03 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
PurchaseAmerican Depositary Shares | 52,656 | $13.80 | $726,863.42 |
DisclosureSEC source: 0000950170-24-137446 · ownership.xml · nonDerivative · entry 7 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 871,714 F11 · price: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $13.48 to $14.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote. F2 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. F3 · ownership.nature: Baker Bros. Advisors LP ("the Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by or held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F5 · ownership.nature: Includes beneficial ownership of 12,000 ADS issuable upon the vesting of restricted stock units (each an "RSU") payable solely in ADS previously issued to Felix J. Baker, in his capacity as a director of the Issuer pursuant to the Issuer's 2020 Equity Incentive Plan (the "2020 Plan") of which the Funds may be deemed to own a portion. The RSUs vest in three equal annual installments beginning on April 18, 2025, subject to Felix J. Baker's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Felix J. Baker serves on the Board as a representative of the Funds and their affiliates and control persons. Each RSU represents a contingent right to receive one Ordinary Share of the Issuer. F6 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the ADS received upon vesting of RSUs and non-qualified share options convertible solely into ADS of the Issuer ("Share Options") received as a result of his service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the ADS upon vesting of RSUs, Share Options, and ADS received upon the exercise of Share Options (i.e. no direct pecuniary interest) issued as compensation for such Board service. F7 · ownership.nature: The Adviser has voting and dispositive power over the Share Options, RSUs and any ADS received as a result of the exercise of Share Options or vesting of RSUs. Read SEC document |
| December 13, 2024 Filed Dec 17, 2024 23:03 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
PurchaseAmerican Depositary Shares | 244,587 | $13.72 | $3,356,760.91 |
DisclosureSEC source: 0000950170-24-137446 · ownership.xml · nonDerivative · entry 6 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 8,970,829 F10 · price: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $13.44 to $13.81, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote. F3 · ownership.nature: Baker Bros. Advisors LP ("the Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by or held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F5 · ownership.nature: Includes beneficial ownership of 12,000 ADS issuable upon the vesting of restricted stock units (each an "RSU") payable solely in ADS previously issued to Felix J. Baker, in his capacity as a director of the Issuer pursuant to the Issuer's 2020 Equity Incentive Plan (the "2020 Plan") of which the Funds may be deemed to own a portion. The RSUs vest in three equal annual installments beginning on April 18, 2025, subject to Felix J. Baker's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Felix J. Baker serves on the Board as a representative of the Funds and their affiliates and control persons. Each RSU represents a contingent right to receive one Ordinary Share of the Issuer. F6 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the ADS received upon vesting of RSUs and non-qualified share options convertible solely into ADS of the Issuer ("Share Options") received as a result of his service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the ADS upon vesting of RSUs, Share Options, and ADS received upon the exercise of Share Options (i.e. no direct pecuniary interest) issued as compensation for such Board service. F7 · ownership.nature: The Adviser has voting and dispositive power over the Share Options, RSUs and any ADS received as a result of the exercise of Share Options or vesting of RSUs. F8 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. Read SEC document |
| December 13, 2024 Filed Dec 17, 2024 23:03 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
PurchaseAmerican Depositary Shares | 22,722 | $13.72 | $311,841.27 |
DisclosureSEC source: 0000950170-24-137446 · ownership.xml · nonDerivative · entry 5 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 819,058 F10 · price: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $13.44 to $13.81, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote. F2 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. F3 · ownership.nature: Baker Bros. Advisors LP ("the Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by or held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F5 · ownership.nature: Includes beneficial ownership of 12,000 ADS issuable upon the vesting of restricted stock units (each an "RSU") payable solely in ADS previously issued to Felix J. Baker, in his capacity as a director of the Issuer pursuant to the Issuer's 2020 Equity Incentive Plan (the "2020 Plan") of which the Funds may be deemed to own a portion. The RSUs vest in three equal annual installments beginning on April 18, 2025, subject to Felix J. Baker's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Felix J. Baker serves on the Board as a representative of the Funds and their affiliates and control persons. Each RSU represents a contingent right to receive one Ordinary Share of the Issuer. F6 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the ADS received upon vesting of RSUs and non-qualified share options convertible solely into ADS of the Issuer ("Share Options") received as a result of his service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the ADS upon vesting of RSUs, Share Options, and ADS received upon the exercise of Share Options (i.e. no direct pecuniary interest) issued as compensation for such Board service. F7 · ownership.nature: The Adviser has voting and dispositive power over the Share Options, RSUs and any ADS received as a result of the exercise of Share Options or vesting of RSUs. Read SEC document |
| December 13, 2024 Filed Dec 17, 2024 23:03 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
PurchaseAmerican Depositary Shares | 59,995 | $13.63 | $817,659.86 |
DisclosureSEC source: 0000950170-24-137446 · ownership.xml · nonDerivative · entry 4 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 8,726,242 F9 · price: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $13.42 to $13.89, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote. F3 · ownership.nature: Baker Bros. Advisors LP ("the Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by or held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F5 · ownership.nature: Includes beneficial ownership of 12,000 ADS issuable upon the vesting of restricted stock units (each an "RSU") payable solely in ADS previously issued to Felix J. Baker, in his capacity as a director of the Issuer pursuant to the Issuer's 2020 Equity Incentive Plan (the "2020 Plan") of which the Funds may be deemed to own a portion. The RSUs vest in three equal annual installments beginning on April 18, 2025, subject to Felix J. Baker's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Felix J. Baker serves on the Board as a representative of the Funds and their affiliates and control persons. Each RSU represents a contingent right to receive one Ordinary Share of the Issuer. F6 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the ADS received upon vesting of RSUs and non-qualified share options convertible solely into ADS of the Issuer ("Share Options") received as a result of his service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the ADS upon vesting of RSUs, Share Options, and ADS received upon the exercise of Share Options (i.e. no direct pecuniary interest) issued as compensation for such Board service. F7 · ownership.nature: The Adviser has voting and dispositive power over the Share Options, RSUs and any ADS received as a result of the exercise of Share Options or vesting of RSUs. F8 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. Read SEC document |
| December 13, 2024 Filed Dec 17, 2024 23:03 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
PurchaseAmerican Depositary Shares | 5,573 | $13.63 | $75,953.30 |
DisclosureSEC source: 0000950170-24-137446 · ownership.xml · nonDerivative · entry 3 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 796,336 F9 · price: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $13.42 to $13.89, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote. F2 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. F3 · ownership.nature: Baker Bros. Advisors LP ("the Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by or held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F5 · ownership.nature: Includes beneficial ownership of 12,000 ADS issuable upon the vesting of restricted stock units (each an "RSU") payable solely in ADS previously issued to Felix J. Baker, in his capacity as a director of the Issuer pursuant to the Issuer's 2020 Equity Incentive Plan (the "2020 Plan") of which the Funds may be deemed to own a portion. The RSUs vest in three equal annual installments beginning on April 18, 2025, subject to Felix J. Baker's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Felix J. Baker serves on the Board as a representative of the Funds and their affiliates and control persons. Each RSU represents a contingent right to receive one Ordinary Share of the Issuer. F6 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the ADS received upon vesting of RSUs and non-qualified share options convertible solely into ADS of the Issuer ("Share Options") received as a result of his service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the ADS upon vesting of RSUs, Share Options, and ADS received upon the exercise of Share Options (i.e. no direct pecuniary interest) issued as compensation for such Board service. F7 · ownership.nature: The Adviser has voting and dispositive power over the Share Options, RSUs and any ADS received as a result of the exercise of Share Options or vesting of RSUs. Read SEC document |
| December 13, 2024 Filed Dec 17, 2024 23:03 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
PurchaseAmerican Depositary Shares | 30,241 | $13.50 | $408,189.99 |
DisclosureSEC source: 0000950170-24-137446 · ownership.xml · nonDerivative · entry 2 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 8,666,247 F1 · price: The price reported in Column 4 is a weighted average price. These American Depositary Shares ("ADS") of Bicycle Therapeutics plc (the "Issuer") were traded by 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $13.32 to $13.50, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote. F3 · ownership.nature: Baker Bros. Advisors LP ("the Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by or held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F5 · ownership.nature: Includes beneficial ownership of 12,000 ADS issuable upon the vesting of restricted stock units (each an "RSU") payable solely in ADS previously issued to Felix J. Baker, in his capacity as a director of the Issuer pursuant to the Issuer's 2020 Equity Incentive Plan (the "2020 Plan") of which the Funds may be deemed to own a portion. The RSUs vest in three equal annual installments beginning on April 18, 2025, subject to Felix J. Baker's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Felix J. Baker serves on the Board as a representative of the Funds and their affiliates and control persons. Each RSU represents a contingent right to receive one Ordinary Share of the Issuer. F6 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the ADS received upon vesting of RSUs and non-qualified share options convertible solely into ADS of the Issuer ("Share Options") received as a result of his service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the ADS upon vesting of RSUs, Share Options, and ADS received upon the exercise of Share Options (i.e. no direct pecuniary interest) issued as compensation for such Board service. F7 · ownership.nature: The Adviser has voting and dispositive power over the Share Options, RSUs and any ADS received as a result of the exercise of Share Options or vesting of RSUs. F8 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. Read SEC document |
| December 13, 2024 Filed Dec 17, 2024 23:03 UTC |
BAKER BROS. ADVISORS LPDirector · 10% owner
667, L.P.Director · 10% owner
Baker Bros. Advisors (GP) LLCDirector · 10% owner
Baker Brothers Life Sciences LPDirector · 10% owner
BAKER FELIXDirector · 10% owner
BAKER JULIANDirector · 10% owner
|
PurchaseAmerican Depositary Shares | 2,809 | $13.50 | $37,915.60 |
DisclosureSEC source: 0000950170-24-137446 · ownership.xml · nonDerivative · entry 1 BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner 667, L.P. · CIK 0001551139 · Director · 10% owner Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner BAKER FELIX · CIK 0001087940 · Director · 10% owner BAKER JULIAN · CIK 0001087939 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 790,763 F1 · price: The price reported in Column 4 is a weighted average price. These American Depositary Shares ("ADS") of Bicycle Therapeutics plc (the "Issuer") were traded by 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $13.32 to $13.50, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote. F2 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the ADS reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. F3 · ownership.nature: Baker Bros. Advisors LP ("the Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by or held for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by or held for the benefit of the Funds. F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose. F5 · ownership.nature: Includes beneficial ownership of 12,000 ADS issuable upon the vesting of restricted stock units (each an "RSU") payable solely in ADS previously issued to Felix J. Baker, in his capacity as a director of the Issuer pursuant to the Issuer's 2020 Equity Incentive Plan (the "2020 Plan") of which the Funds may be deemed to own a portion. The RSUs vest in three equal annual installments beginning on April 18, 2025, subject to Felix J. Baker's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Felix J. Baker serves on the Board as a representative of the Funds and their affiliates and control persons. Each RSU represents a contingent right to receive one Ordinary Share of the Issuer. F6 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker does not have any right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the ADS received upon vesting of RSUs and non-qualified share options convertible solely into ADS of the Issuer ("Share Options") received as a result of his service on the Board. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the ADS upon vesting of RSUs, Share Options, and ADS received upon the exercise of Share Options (i.e. no direct pecuniary interest) issued as compensation for such Board service. F7 · ownership.nature: The Adviser has voting and dispositive power over the Share Options, RSUs and any ADS received as a result of the exercise of Share Options or vesting of RSUs. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 00:43 UTC |
Thompson Travis AlvinCHIEF ACCOUNTING OFFICER
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,109 | $0.00 Strike: $9.82 | $0.00 |
DisclosureSEC source: 0001415889-24-026758 · form4-11142024_121158.xml · derivative · entry 12 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,954 Underlying: Ordinary Shares · 1,109 shares Expires 2029-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024. F7 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 00:43 UTC |
Thompson Travis AlvinCHIEF ACCOUNTING OFFICER
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 154 | $0.00 Strike: $8.21 | $0.00 |
DisclosureSEC source: 0001415889-24-026758 · form4-11142024_121158.xml · derivative · entry 11 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 302 Underlying: Ordinary Shares · 154 shares Expires 2029-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.28836 to GBP 1.00 as of November 11, 2024. F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024. F7 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 00:43 UTC |
Thompson Travis AlvinCHIEF ACCOUNTING OFFICER
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,312 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001415889-24-026758 · form4-11142024_121158.xml · derivative · entry 10 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,617 Underlying: Ordinary Shares · 1,312 shares Expires 2028-09-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.28836 to GBP 1.00 as of November 11, 2024. F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024. F7 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 00:43 UTC |
Thompson Travis AlvinCHIEF ACCOUNTING OFFICER
|
SaleOrdinary Shares | 231 | $24.82 | $5,733.42 |
DisclosureSEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 9 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,241 F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.82 to $24.825 inclusive. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 00:43 UTC |
Thompson Travis AlvinCHIEF ACCOUNTING OFFICER
|
SaleOrdinary Shares | 209 | $24.77 | $5,176.93 |
DisclosureSEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 8 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,472 F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.73 to $24.81 inclusive. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 00:43 UTC |
Thompson Travis AlvinCHIEF ACCOUNTING OFFICER
|
SaleOrdinary Shares | 3,241 | $25.21 | $81,705.61 |
DisclosureSEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 7 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,681 F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 00:43 UTC |
Thompson Travis AlvinCHIEF ACCOUNTING OFFICER
|
SaleOrdinary Shares | 1,109 | $25.05 | $27,780.45 |
DisclosureSEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 6 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,922 F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4), (5) and (6). Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 00:43 UTC |
Thompson Travis AlvinCHIEF ACCOUNTING OFFICER
|
Exercise / conversionOrdinary Shares | 1,109 | $9.82 | $10,890.38 |
DisclosureSEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 5 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 00:43 UTC |
Thompson Travis AlvinCHIEF ACCOUNTING OFFICER
|
SaleOrdinary Shares | 154 | $25.01 | $3,851.54 |
DisclosureSEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 4 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,922 F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.08 inclusive. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 00:43 UTC |
Thompson Travis AlvinCHIEF ACCOUNTING OFFICER
|
Exercise / conversionOrdinary Shares | 154 | $8.21 | $1,264.34 |
DisclosureSEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 3 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024. F2 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.28836 to GBP 1.00 as of November 11, 2024. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 00:43 UTC |
Thompson Travis AlvinCHIEF ACCOUNTING OFFICER
|
SaleOrdinary Shares | 1,312 | $25.05 | $32,865.60 |
DisclosureSEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 2 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,922 F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4), (5) and (6). Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 00:43 UTC |
Thompson Travis AlvinCHIEF ACCOUNTING OFFICER
|
Exercise / conversionOrdinary Shares | 1,312 | $1.87 | $2,453.44 |
DisclosureSEC source: 0001415889-24-026758 · form4-11142024_121158.xml · nonDerivative · entry 1 Thompson Travis Alvin · CIK 0001983944 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 13, 2024. F2 · price: This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of $1.28836 to GBP 1.00 as of November 11, 2024. Read SEC document |
| October 03, 2024 Filed Oct 4, 2024 20:50 UTC |
Hannay Michael Charles FergusonCHIEF PROD & SUPPLY CHAIN OFF
|
SaleOrdinary Shares | 247 | $22.26 | $5,498.22 |
DisclosureSEC source: 0001415889-24-024771 · form4-10042024_041010.xml · nonDerivative · entry 1 Hannay Michael Charles Ferguson · CIK 0002015378 · CHIEF PROD & SUPPLY CHAIN OFF 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,398 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.91 to $22.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.